425: NorthView Acquisition Corp. Amends Merger Agreement with Profusa, Secures $22.2 Million Convertible Note Financing
Form 8-K Filing
NorthView Acquisition Corp. revises its merger agreement with Profusa, extending milestone deadlines and adjusting financial targets, while also securing a $22.2 million convertible note financing to support the business combination.
Summary
- NorthView Acquisition Corp. has amended its merger agreement with Profusa, Inc., adjusting the Company Reference Value to account for financing proceeds, debt conversions, and incentive shares.
- Milestone Event III, concerning the APAC Joint Venture, has been extended from December 31, 2024, to December 31, 2025.
- Milestone Event IV's earnout revenue target has been changed from $99.7 million for 2025 to $11.864 million for 2026.
- NorthView entered into a securities purchase agreement for up to $22.2 million in senior secured convertible promissory notes with an institutional investor.
- The investor will purchase up to $22,222,222 of Convertible Notes for a purchase price of up to $20,000,000, after a 10% original issue discount (OID).
- An initial closing of $10 million in notes will occur at the consummation of the business combination, with subsequent tranches available based on registration statement effectiveness, trading volume, and stock price thresholds.
- The Convertible Notes will mature 18 months from their respective closing dates and are convertible at the lower of $10 or 95% of the lowest daily volume-weighted average price per share in the 10 trading days prior to the original issue date.
- Interest accrues at 10% per annum, increasing to 24% upon an event of default.
- Certain holders of NorthView common stock will enter into a lock-up agreement restricting the sale or transfer of their shares.
- NorthView has filed a registration statement/proxy statement on Form S-4 with the SEC regarding the proposed business combination.
Sentiment
Score: 5
Explanation: The sentiment is neutral. While securing financing is positive, the amendment to the merger agreement and the terms of the convertible notes introduce risks and uncertainties.
Positives
- The $22.2 million convertible note financing provides capital to support the business combination with Profusa.
- The extension of the APAC Joint Venture milestone provides Profusa with additional time to consummate the joint venture and receive related funding.
- The revised earnout revenue target for 2026 may be more achievable, potentially increasing the likelihood of Profusa receiving earnout payments.
- The lock-up agreements provide stability by restricting the sale or transfer of shares by certain NorthView common stock holders.
Negatives
- The amendment to the merger agreement suggests that Profusa may have been unable to meet the original milestones and financial targets.
- The convertible notes include a 10% original issue discount, reducing the net proceeds received by NorthView.
- The convertible notes accrue interest at 10% per annum, increasing to 24% upon an event of default, which could create a significant financial burden.
- The conversion price of the notes is subject to adjustment based on down-round and most-favored nation price and terms protections, which could result in significant dilution to existing shareholders.
Risks
- Failure to complete the business combination with Profusa could result in NorthView being unable to utilize the financing.
- Profusa may be unable to achieve the revised earnout revenue target for 2026, resulting in a loss of potential earnout payments.
- The convertible notes contain events of default that could trigger acceleration of the debt.
- The conversion of the notes could result in significant dilution to existing shareholders.
- The market conditions may make it impracticable or inadvisable to purchase the Purchased Securities at the Initial Closing.
Future Outlook
The document contains forward-looking statements regarding the anticipated benefits of the proposed transaction, the combined company becoming a publicly listed company, the anticipated impact of the proposed transaction on the combined companies business and future financial and operating results, the anticipated timing of closing of the proposed transaction, the success and customer acceptance of Profusas product and service offerings, and other aspects of Profusas operations or operating results.
Industry Context
The announcement reflects the ongoing trend of SPACs seeking to complete business combinations, often requiring amendments to initial agreements and additional financing to ensure deal completion. The extension of milestone deadlines and adjustments to financial targets are common in such transactions, reflecting the challenges of integrating and scaling businesses.
Comparison to Industry Standards
- SPAC transactions often involve adjustments to deal terms, reflecting the dynamic nature of the target companies and market conditions.
- Convertible note financings are a common tool for SPACs to raise capital, but the terms can vary significantly depending on the company's risk profile and the investor's required return.
- Lock-up agreements are standard practice to prevent significant stock sales immediately following a merger, providing stability for the newly combined company.
Stakeholder Impact
- Shareholders may experience dilution from the conversion of the notes.
- Employees of Profusa may be impacted by the revised milestones and financial targets.
- Customers and suppliers of Profusa may be impacted by the business combination and any changes to the company's strategy.
Next Steps
- Consummation of the business combination with Profusa.
- Initial closing of the convertible note financing.
- Filing of required documents with the SEC and Nasdaq.
- Achievement of milestones related to the APAC Joint Venture and earnout revenue targets.
Key Dates
| Date | Description |
|---|---|
| November 7, 2022 | Original Merger Agreement and Plan of Reorganization date. |
| September 12, 2023 | Amendment No. 1 to Merger Agreement date. |
| January 12, 2024 | Amendment No. 2 to Merger Agreement date. |
| March 4, 2024 | Amendment No. 3 to Merger Agreement date. |
| December 31, 2024 | Original deadline for Profusa to consummate the APAC Joint Venture and receive related funding (Milestone Event III). |
| February 11, 2025 | Amendment No. 4 to Merger Agreement and Securities Purchase Agreement date. |
| March 22, 2025 | Amended date for Section 9.01 of the Merger Agreement. |
| December 31, 2025 | Extended deadline for Profusa to consummate the APAC Joint Venture and receive related funding (Milestone Event III). |
| December 31, 2026 | Date for achievement of Earnout Revenue of $11,864,000 (Milestone Event IV). |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.